Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18742986 | METHODS AND PRODUCTS FOR GENETIC ENGINEERING | June 2024 | March 2025 | Allow | 9 | 1 | 0 | Yes | No |
| 17270341 | BINDING PROTEIN OF NS1 PROTEIN | April 2024 | February 2025 | Allow | 47 | 2 | 0 | No | No |
| 18440344 | ANTIBODIES AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF EPSTEIN BARR VIRUS INFECTION | February 2024 | May 2025 | Allow | 15 | 1 | 1 | No | No |
| 18435026 | MODIFIED CYTOMEGALOVIRUS PROTEINS AND STABILIZED COMPLEXES | February 2024 | April 2025 | Allow | 14 | 1 | 1 | Yes | No |
| 18506578 | HUMAN CYTOMEGALOVIRUS GB POLYPEPTIDE | November 2023 | June 2025 | Allow | 19 | 1 | 0 | No | No |
| 18496076 | Recombinant Cytomegalovirus Vectors As Vaccines For Tuberculosis | October 2023 | June 2025 | Allow | 19 | 2 | 0 | No | No |
| 18488604 | METHODS AND COMPOSITIONS FOR ANTIBODY-EVADING VIRUS VECTORS | October 2023 | February 2025 | Abandon | 16 | 0 | 1 | No | No |
| 18481204 | HERPES SIMPLEX VIRUS VACCINE | October 2023 | March 2025 | Abandon | 17 | 1 | 0 | No | No |
| 18474014 | METHODS OF MAKING FUCOSYLATED AND AFUCOSYLATED FORMS OF A PROTEIN | September 2023 | April 2025 | Allow | 19 | 1 | 0 | No | No |
| 18458657 | LIGAND DISCOVERY AND GENE DELIVERY VIA RETROVIRAL SURFACE DISPLAY | August 2023 | September 2024 | Allow | 13 | 2 | 0 | Yes | No |
| 18452624 | MULTIVALENT RECOMBINANT AVIAN HERPES VIRUSES AND VACCINES FOR IMMUNIZING AVIAN SPECIES | August 2023 | June 2025 | Allow | 22 | 2 | 0 | No | No |
| 18232437 | VETO CELLS GENERATED FROM MEMORY T CELLS | August 2023 | April 2025 | Allow | 20 | 1 | 0 | No | No |
| 18358350 | EPSTEIN-BARR VIRUS ANTIGEN CONSTRUCTS | July 2023 | January 2025 | Allow | 18 | 1 | 1 | Yes | No |
| 18355265 | DEVELOPMENT OF DENGUE VIRUS VACCINE COMPONENTS | July 2023 | September 2024 | Allow | 14 | 1 | 0 | No | No |
| 18354574 | HERPES SIMPLEX VIRUS VACCINE | July 2023 | March 2025 | Abandon | 20 | 1 | 0 | No | No |
| 18351392 | COMPOSITIONS AND METHODS FOR INDUCING IMMUNE RESPONSES | July 2023 | April 2025 | Allow | 21 | 2 | 0 | No | No |
| 18345893 | CORONAVIRUS VACCINE COMPOSITIONS AND METHODS | June 2023 | September 2024 | Allow | 15 | 1 | 0 | Yes | No |
| 18335810 | HBV VACCINES AND METHODS TREATING HBV | June 2023 | May 2025 | Allow | 23 | 2 | 1 | Yes | No |
| 18334279 | MVA VACCINE FOR DELIVERY OF A UL128 COMPLEX AND PREVENTING CMV INFECTION | June 2023 | July 2024 | Allow | 13 | 1 | 0 | No | No |
| 18333718 | SCALABLE PURIFICATION METHOD FOR AAV1 | June 2023 | July 2024 | Allow | 13 | 1 | 0 | No | No |
| 18200997 | ANTIGEN DELIVERY PLATFORMS | May 2023 | December 2024 | Abandon | 19 | 1 | 0 | No | No |
| 18318061 | VACCINES AGAINST ZIKA VIRUS | May 2023 | May 2025 | Allow | 24 | 2 | 0 | Yes | No |
| 18141055 | Identification and Attenuation of the Immunosuppressive Domains in Fusion Proteins of Enveloped RNA Viruses | April 2023 | January 2025 | Abandon | 20 | 1 | 0 | No | No |
| 18297207 | SELF-ASSEMBLING PROTEIN NANOPARTICLES ENCAPSULATING IMMUNOSTIMULATORY NUCLEID ACIDS | April 2023 | January 2025 | Abandon | 21 | 1 | 0 | No | No |
| 18130375 | METHODS AND PRODUCTS FOR GENETIC ENGINEERING | April 2023 | September 2024 | Allow | 18 | 1 | 0 | Yes | No |
| 18189512 | RESPIRATORY VIRUS NUCLEIC ACID VACCINES | March 2023 | December 2024 | Abandon | 21 | 1 | 0 | No | No |
| 18183066 | TETRAVALENT ANTI-PSGL-1 ANTIBODIES AND USES THEREOF | March 2023 | December 2024 | Abandon | 21 | 1 | 0 | No | No |
| 18182212 | MEANS AND METHODS FOR TREATING HERPESVIRUS INFECTION | March 2023 | May 2025 | Allow | 26 | 2 | 0 | No | No |
| 18176014 | NUCLEIC ACID VACCINES FOR VARICELLA ZOSTER VIRUS (VZV) | February 2023 | November 2024 | Abandon | 20 | 2 | 0 | No | No |
| 18165770 | ONCOLYTIC VIRAL VECTORS AND USES THEREOF | February 2023 | October 2024 | Allow | 20 | 1 | 0 | Yes | No |
| 18060386 | STABLE FORMULATIONS OF CYTOMEGALOVIRUS | November 2022 | March 2025 | Abandon | 27 | 3 | 0 | No | No |
| 18071109 | HSV-2-DELTA-gD VACCINES AND METHODS FOR THEIR PRODUCTION AND USE | November 2022 | July 2024 | Allow | 20 | 2 | 0 | No | No |
| 17938823 | ZOONOTIC DISEASE RNA VACCINES | October 2022 | June 2025 | Abandon | 32 | 3 | 0 | No | No |
| 17812732 | RECOMBINANT HVT VECTORS EXPRESSING MULTIPLE ANTIGENS OF AVIAN PATHOGENS AND USES THEREOF | July 2022 | April 2025 | Allow | 33 | 4 | 0 | Yes | No |
| 17852891 | EXOGENOUS GENE EXPRESSION IN RECOMBINANT ADENOVIRUS FOR MINIMAL IMPACT ON VIRAL KINETICS | June 2022 | December 2024 | Allow | 29 | 2 | 0 | Yes | No |
| 17840478 | HUMAN CYTOMEGALOVIRUS VACCINE | June 2022 | November 2024 | Abandon | 29 | 3 | 0 | No | No |
| 17670052 | COMPOSITIONS AND METHODS FOR TREATMENT OF CYTOMEGALOVIRUS | February 2022 | June 2025 | Allow | 40 | 1 | 0 | No | No |
| 17628351 | MODIFIED HUMAN CYTOMEGALOVIRUS PROTEINS | January 2022 | June 2025 | Allow | 41 | 1 | 0 | No | No |
| 17577681 | METHODS AND COMPOSITIONS FOR TREATING INFECTIONS | January 2022 | October 2024 | Allow | 33 | 1 | 0 | No | No |
| 17510969 | VACCINATION USING HERPESVIRUS GENOMES IN NUCLEIC ACID FORM | October 2021 | June 2025 | Allow | 44 | 1 | 0 | No | No |
| 17475001 | VACCINE FOR USE AGAINST CORONAVIRUS AND VARIANTS THEREOF | September 2021 | March 2025 | Allow | 42 | 3 | 0 | No | No |
| 17407716 | MODIFIED CAPSID PROTEINS FOR ENHANCED DELIVERY OF PARVOVIRUS VECTORS | August 2021 | February 2025 | Allow | 41 | 4 | 0 | No | Yes |
| 17431856 | MULTIVALENT KAPOSI SARCOMA-ASSOCIATED HERPESVIRUS-LIKE PARTICLES AND USES THEREOF | August 2021 | July 2024 | Allow | 35 | 1 | 0 | Yes | No |
| 17420529 | PASSIVE TRANSFER OF IMMUNITY USING RECOMBINANT HERPES SIMPLEX VIRUS 2 (HSV-2) VACCINE VECTORS | July 2021 | May 2025 | Abandon | 46 | 2 | 0 | No | No |
| 17300287 | REPLICATION-COMPETENT CONTROLLED ALPHA-HERPESVIRUS VECTORS AND USES THEREFORE | May 2021 | November 2024 | Allow | 42 | 4 | 0 | No | No |
| 17290384 | RESPIRATORY SYNCYTIAL VIRUS RECOMBINANT F PROTEIN AND VACCINE COMPOSITION CONTAINING SAME | April 2021 | April 2025 | Allow | 47 | 1 | 0 | No | No |
| 17287698 | CANINE DISTEMPER VACCINES AND METHODS OF TREATMENT USING THE SAME | April 2021 | April 2025 | Allow | 48 | 3 | 0 | No | No |
| 17231534 | VACCINES HAVING AN ANTIGEN AND INTERLEUKIN-21 AS AN ADJUVANT | April 2021 | July 2024 | Allow | 40 | 3 | 0 | Yes | No |
| 17280803 | RECOMBINANT VIRAL VECTOR, IMMUNE COMPOSITION CONTAINING SAME, AND USE THEREOF | March 2021 | September 2024 | Allow | 41 | 2 | 0 | No | No |
| 17273977 | Storage Improved Poxvirus Compositions | March 2021 | July 2024 | Allow | 41 | 2 | 0 | No | No |
| 17272158 | NS1-BINDING PROTEIN | February 2021 | April 2025 | Allow | 50 | 2 | 0 | No | No |
| 17272096 | NS1-BINDING PROTEIN | February 2021 | January 2025 | Allow | 47 | 2 | 0 | Yes | No |
| 17271287 | Recombinant Replication Competent Viruses Comprising a Coding Region for Glycogen Synthase Kinase-3 (GSK3) and Methods of Killing Aberrant Cells | February 2021 | December 2024 | Allow | 46 | 2 | 0 | No | No |
| 17269409 | VACCINES AGAINST NIPAH VIRUS, AND METHODS OF USING SAME | February 2021 | March 2025 | Allow | 49 | 3 | 0 | No | No |
| 17264377 | METHODS AND COMPOSITIONS FOR ALPHAVIRUS VACCINE | January 2021 | February 2025 | Abandon | 48 | 3 | 0 | Yes | No |
| 17255517 | INFLUENZA VIRUS HEMAGGLUTININ MUTANTS | December 2020 | May 2025 | Allow | 53 | 2 | 1 | Yes | No |
| 17091756 | FORMULATIONS OF ANTIBODY MOLECULES TO INFLUENZA VIRUS | November 2020 | November 2024 | Allow | 48 | 4 | 0 | No | No |
| 16982039 | VACCINE COMPOSITIONS | September 2020 | May 2025 | Allow | 56 | 4 | 0 | No | No |
| 16888398 | IMMUNOTHERAPEUTIC COMPOSITIONS FOR TREATMENT OF GLIOBLASTOMA MULTIFORME | May 2020 | January 2025 | Abandon | 55 | 3 | 0 | No | Yes |
| 16765285 | EPSTEIN-BARR VIRUS VACCINES | May 2020 | May 2025 | Abandon | 60 | 7 | 0 | No | No |
| 16762286 | PHARMACEUTICAL COMPOSITIONS, METHODS FOR PREPARATION COMPRISING SIZING OF LIPID VESICLE PARTICLES, AND USES THEREOF | May 2020 | February 2025 | Abandon | 57 | 4 | 0 | No | No |
| 16741827 | ENGINEERED HERPES SIMPLEX VIRUS-1 (HSV-1) VECTORS AND USES THEREOF | January 2020 | September 2024 | Allow | 56 | 4 | 0 | No | No |
| 16738692 | COMPOSITIONS AND METHODS FOR ENHANCING IMMUNE RESPONSE TO VACCINATION AND IMPROVING VACCINE PRODUCTION | January 2020 | May 2023 | Abandon | 40 | 4 | 1 | No | Yes |
| 16017173 | LOW, IMMUNE ENHANCING, DOSE MTOR INHIBITORS AND USES THEREOF | June 2018 | February 2019 | Allow | 8 | 1 | 0 | Yes | No |
| 15767609 | BROAD SPECTRUM INFLUENZA VIRUS VACCINE | April 2018 | July 2020 | Abandon | 27 | 10 | 0 | Yes | No |
| 15762050 | DESIGN AND CHARACTERIZATION OF INFLUENZA VACCINES | March 2018 | July 2019 | Allow | 16 | 2 | 0 | No | No |
| 15574274 | VERSATILE INFLUENZA VIRUS VACCINE COMPOSITION | November 2017 | September 2018 | Allow | 10 | 1 | 0 | Yes | No |
| 15798388 | COMPOSITIONS AND METHODS TO INHIBIT VIRAL REPLICATION | October 2017 | November 2019 | Allow | 24 | 1 | 1 | Yes | No |
| 15546422 | HUMAN MONOCLONAL ANTIBODIES ENDOWED WITH STRONG NEUTRALIZING ACTIVITY AGAINST HSV-1 AND HSV-2 | July 2017 | January 2020 | Allow | 30 | 3 | 0 | No | No |
| 15335847 | ANTI-FACTOR D ANTIBODIES AND CONJUGATES | October 2016 | April 2019 | Allow | 30 | 1 | 1 | Yes | No |
| 15331513 | VACCINE ANTIGENS THAT DIRECT IMMUNITY TO CONSERVED EPITOPES | October 2016 | May 2018 | Allow | 19 | 1 | 0 | Yes | No |
| 15292088 | LOW, IMMUNE ENHANCING, DOSE MTOR INHIBITORS AND USES THEREOF | October 2016 | May 2018 | Allow | 19 | 2 | 0 | Yes | No |
| 15215738 | INFLUENZA A H7N9 VIRUS THERAPIES | July 2016 | October 2017 | Allow | 14 | 1 | 0 | No | No |
| 15167204 | COMPOSITIONS AND METHODS TO TREAT HERPES SIMPLEX VIRUS INFECTIONS | May 2016 | June 2018 | Allow | 24 | 2 | 0 | No | No |
| 15030843 | COMPOSITIONS AND METHODS FOR DETECTION AND DISCRIMINATION OF INFLUENZA VIRUSES | April 2016 | February 2018 | Allow | 22 | 2 | 1 | Yes | No |
| 15130041 | TAA/ecdCD40L ONCOLYTIC VIRUS | April 2016 | July 2018 | Allow | 27 | 3 | 0 | No | No |
| 14978413 | INFECTIOUS GENOMIC DNA CLONE AND SEROLOGICAL PROFILE OF TORQUE TENO SUS VIRUS 1 AND 2 | December 2015 | April 2018 | Allow | 28 | 2 | 0 | Yes | No |
| 14796345 | METHODS TO PRODUCE BUNYAVIRUS REPLICON PARTICLES | July 2015 | January 2017 | Allow | 18 | 1 | 0 | Yes | No |
| 14727666 | ANTIGENIC PEPTIDE OF HSV-2 AND METHODS FOR USING SAME | June 2015 | October 2016 | Allow | 16 | 1 | 0 | No | No |
| 14485513 | COMPOSITIONS AND METHODS FOR VACCINATING AGAINST HSV-2 | September 2014 | July 2015 | Allow | 10 | 0 | 0 | Yes | No |
| 14479245 | SYSTEMS AND METHODS FOR DETECTING INFECTIOUS DISEASES | September 2014 | June 2016 | Allow | 21 | 4 | 1 | Yes | No |
| 14360931 | HEPATITIS B VIRUS MUTANT, MUTANT AMPLIFICATION KIT AND USE THEREOF | August 2014 | October 2016 | Allow | 29 | 1 | 2 | Yes | No |
| 14460230 | COMPOSITIONS AND METHODS FOR VACCINATING AGAINST HSV-2 | August 2014 | June 2015 | Allow | 10 | 0 | 0 | Yes | No |
| 14310138 | ANTIBODIES FOR ONCOGENIC STRAINS OF HPV AND METHODS OF THEIR USE | June 2014 | November 2016 | Allow | 29 | 2 | 1 | Yes | No |
| 14297486 | ANTI-HUMAN RESPIRATORY SYNCYTIAL VIRUS (RSV) ANTIBODIES AND METHODS OF USE | June 2014 | January 2016 | Allow | 19 | 1 | 1 | Yes | No |
| 14116814 | PRODUCTION OF DENSE BODIES (DB) FROM HCMV-INFECTED CELLS | March 2014 | August 2016 | Allow | 33 | 2 | 1 | Yes | No |
| 14176813 | CODON-OPTIMIZED POLYNUCLEOTIDE-BASED VACCINES AGAINST HUMAN CYTOMEGALOVIRUS INFECTION | February 2014 | June 2015 | Allow | 17 | 1 | 0 | Yes | No |
| 14233710 | ADENOVIRUSES AND THEIR USE | January 2014 | August 2015 | Allow | 19 | 1 | 1 | Yes | No |
| 13983279 | Methods and Compositions for Pseudoinfectious Alphaviruses | November 2013 | February 2016 | Allow | 31 | 1 | 1 | Yes | No |
| 14006222 | IMMUNE SUPPRESSOR AND ITS USE | September 2013 | January 2018 | Allow | 52 | 4 | 1 | No | No |
| 14004501 | Method of Viral Production in Cells | September 2013 | September 2017 | Allow | 48 | 4 | 1 | Yes | Yes |
| 13931028 | FUSION PROTEINS AND METHODS OF USE | June 2013 | October 2014 | Allow | 15 | 1 | 1 | Yes | No |
| 13822794 | METHODS TO PRODUCE BUNYAVIRUS REPLICON PARTICLES | May 2013 | April 2015 | Allow | 25 | 1 | 1 | Yes | No |
| 13809397 | ANTI-HUMAN RESPIRATORY SYNCYTIAL VIRUS (RSV) ANTIBODIES AND METHODS OF USE | March 2013 | May 2015 | Allow | 28 | 2 | 1 | Yes | No |
| 13843176 | COMPOSITIONS AND METHODS FOR VACCINATING AGAINST HSV-2 | March 2013 | May 2014 | Allow | 14 | 1 | 1 | Yes | No |
| 13843093 | COMPOSITIONS AND METHODS FOR VACCINATING AGAINST HSV-2 | March 2013 | May 2014 | Allow | 14 | 1 | 1 | Yes | No |
| 13842964 | COMPOSITIONS AND METHODS FOR VACCINATING AGAINST HSV-2 | March 2013 | May 2014 | Allow | 14 | 1 | 1 | Yes | No |
| 13841691 | IDIOTYPIC ANTIBODIES AND USES THEREOF | March 2013 | May 2015 | Allow | 26 | 1 | 1 | Yes | No |
| 13840805 | INFECTIOUS GENOMIC DNA CLONE AND SEROLOGICAL PROFILE OF TORQUE TENO SUS VIRUS 1 AND 2 | March 2013 | September 2015 | Allow | 30 | 2 | 1 | Yes | No |
| 13789281 | Methods and Compositions for Dengue Virus 3 (DV3) Infectious Clone | March 2013 | July 2014 | Allow | 17 | 1 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner GILL, RACHEL B.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 20.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner GILL, RACHEL B works in Art Unit 1671 and has examined 111 patent applications in our dataset. With an allowance rate of 82.9%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 26 months.
Examiner GILL, RACHEL B's allowance rate of 82.9% places them in the 50% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by GILL, RACHEL B receive 2.11 office actions before reaching final disposition. This places the examiner in the 70% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by GILL, RACHEL B is 26 months. This places the examiner in the 60% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +28.6% benefit to allowance rate for applications examined by GILL, RACHEL B. This interview benefit is in the 80% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 24.1% of applications are subsequently allowed. This success rate is in the 25% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 55.8% of cases where such amendments are filed. This entry rate is in the 78% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 93% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 85% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 54.5% are granted (fully or in part). This grant rate is in the 68% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 3% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.